Anti-inflammatory effects of empagliflozin in patients with type 2 diabetes and insulin resistance

BACKGROUND: Inflammation might be a pathological mediator of cardiovascular events in patients with type 2 diabetes and high cardiovascular risk. METHODS: We investigated whether empagliflozin (EMPA) exerts anti-inflammatory effects that are reflected in decreased high-sensitivity C-reactive protein...

Descripción completa

Detalles Bibliográficos
Autor principal: Hattori, Sachiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6299593/
https://www.ncbi.nlm.nih.gov/pubmed/30574207
http://dx.doi.org/10.1186/s13098-018-0395-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6299593/
https://www.ncbi.nlm.nih.gov/pubmed/30574207
http://dx.doi.org/10.1186/s13098-018-0395-5

Ejemplares similares